Rethinking Routine Use of Anthracyclines for Breast Cancer in the Modern Era

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.

The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.

Advances in endocrine therapy, immunotherapy, and ADCs frame unresolved breast cancer treatment questions ahead of BTG 2026.

Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.

See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.

Erica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant for ESR1-mutated HR+/HER2– breast cancer and the importance of ctDNA monitoring.